Standard BioTools Inc. Effective Tax Rate
Standard BioTools Inc. (LAB) reported Effective Tax Rate of 39.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-03-16
- Standard BioTools Inc. effective income tax rate reconciliation, percent for the quarter ending 2023-03-31 was -1.60%, a 328.57% decline year-over-year.
- Standard BioTools Inc. effective income tax rate reconciliation, percent for the quarter ending 2022-03-31 was 0.70%.
- Standard BioTools Inc. effective income tax rate reconciliation, percent for fiscal 2025 was 39.20%.
- Standard BioTools Inc. effective income tax rate reconciliation, percent for fiscal 2024 was -0.60%.
- Standard BioTools Inc. effective income tax rate reconciliation, percent for fiscal 2023 was -0.60%, a 140.00% decline from fiscal 2022.
- Standard BioTools Inc. effective income tax rate reconciliation, percent for fiscal 2022 was 1.50%, a 78.26% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month | Effective Income Tax Rate Reconciliation, Percent 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 39.20% 10-K · filed 2026-03-16 | |||
| 2024-12-31 | -0.60% 10-K · filed 2026-03-16 | -0.40% 10-K · filed 2025-03-11 | ||
| 2023-12-31 | -0.60% 10-K · filed 2026-03-16 | -0.40% 10-K · filed 2024-03-01 | ||
| 2023-03-31 | -1.60% 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 1.50% 10-K · filed 2025-03-11 | |||
| 2022-09-30 | -1.70% 10-Q · filed 2022-11-09 | |||
| 2022-03-31 | 0.70% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 6.90% 10-K · filed 2023-03-14 | |||
| 2021-09-30 | -6.80% 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | 2.00% 10-K · filed 2022-03-08 | |||
| 2019-12-31 | 2.90% 10-K · filed 2022-03-08 | |||
| 2018-12-31 | 3.90% 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 5.10% 10-K · filed 2020-02-27 | |||
| 2016-12-31 | 5.20% 10-K · filed 2019-03-18 | |||
| 2015-12-31 | 2.60% 10-K · filed 2018-03-08 | |||
| 2014-12-31 | 8.50% 10-K · filed 2017-03-03 | |||
| 2013-12-31 | -0.80% 10-K · filed 2016-02-29 | |||
| 2012-12-31 | -0.70% 10-K · filed 2015-02-26 | |||
| 2011-12-31 | -0.80% 10-K · filed 2014-03-12 | |||
| 2010-12-31 | -0.50% 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |